TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Brief Summary: The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
B: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 28 Days on/off (Placebo 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Brief Summary: The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.


Options:
A: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 28 Days on/off (Placebo 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14)
B: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
D: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short Message System (SMS) Monitoring Intended for the Suicidal Patients: Study of Efficiency
Brief Summary: The study wants to prove that SMS monitoring reduced the number of suicide attempts in six months according to the beginning of its implementation in the group of the patients benefiting SMS compared with the group of patients benefiting from the usual care.


Options:
A: Arm Label: VHS group; Type: EXPERIMENTAL; Interventions: Behavioral: the volitional help sheet | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: the volitional help sheet; Assigned to Arm(s): VHS group
B: Arm Label: Treatment with a probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Treatment with a probiotic | Arm Label: Treatment with placebo powder; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment with placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Treatment with a probiotic; Assigned to Arm(s): Treatment with a probiotic | Intervention Type: OTHER; Name: Treatment with placebo; Assigned to Arm(s): Treatment with placebo powder
C: Arm Label: CARMS therapy + TAU; Type: EXPERIMENTAL; Interventions: Other: Cognitive AppRoaches to coMbatting Suicidality (CARMS) | Arm Label: TAU; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cognitive AppRoaches to coMbatting Suicidality (CARMS); Assigned to Arm(s): CARMS therapy + TAU
D: Arm Label: SMS; Type: EXPERIMENTAL; Interventions: Device: SMS contact with patient after discharge in intervention group | Arm Label: Without SMS; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: SMS contact with patient after discharge in intervention group; Assigned to Arm(s): SMS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short Message System (SMS) Monitoring Intended for the Suicidal Patients: Study of Efficiency
Brief Summary: The study wants to prove that SMS monitoring reduced the number of suicide attempts in six months according to the beginning of its implementation in the group of the patients benefiting SMS compared with the group of patients benefiting from the usual care.


Options:
A: Arm Label: Computer Assisted CIFFTA; Type: EXPERIMENTAL; Interventions: Behavioral: Computer Assisted CIFFTA | Arm Label: Behavioral: Traditional face-to-face treatment-no technology; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral: Traditional face-to-face treatment-no technology | Intervention Type: BEHAVIORAL; Name: Computer Assisted CIFFTA; Assigned to Arm(s): Computer Assisted CIFFTA | Intervention Type: BEHAVIORAL; Name: Behavioral: Traditional face-to-face treatment-no technology; Assigned to Arm(s): Behavioral: Traditional face-to-face treatment-no technology
B: Arm Label: suicide attempt patient who will receive sanitory supervision; Type: OTHER; Interventions: Other: suicide attempt patient using PEPS Program | Arm Label: Suicide attempt patient who will participate to PEPS Program; Type: EXPERIMENTAL; Interventions: Other: suicide attempt patient using PEPS Program | Intervention Type: OTHER; Name: suicide attempt patient using PEPS Program; Assigned to Arm(s): Suicide attempt patient who will participate to PEPS Program, suicide attempt patient who will receive sanitory supervision
C: Arm Label: SMS; Type: EXPERIMENTAL; Interventions: Device: SMS contact with patient after discharge in intervention group | Arm Label: Without SMS; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: SMS contact with patient after discharge in intervention group; Assigned to Arm(s): SMS
D: Arm Label: Psychoeducational intervention (PEI); Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducational intervention (PEI) | Arm Label: Enhanced Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced treatment as usual (ETAU) | Intervention Type: BEHAVIORAL; Name: Psychoeducational intervention (PEI); Assigned to Arm(s): Psychoeducational intervention (PEI) | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual (ETAU); Assigned to Arm(s): Enhanced Treatment as Usual

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short Message System (SMS) Monitoring Intended for the Suicidal Patients: Study of Efficiency
Brief Summary: The study wants to prove that SMS monitoring reduced the number of suicide attempts in six months according to the beginning of its implementation in the group of the patients benefiting SMS compared with the group of patients benefiting from the usual care.


Options:
A: Arm Label: Mindfulness condition; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness | Arm Label: Control condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Mindfulness condition
B: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
C: Arm Label: SMS; Type: EXPERIMENTAL; Interventions: Device: SMS contact with patient after discharge in intervention group | Arm Label: Without SMS; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: SMS contact with patient after discharge in intervention group; Assigned to Arm(s): SMS
D: Arm Label: Control (volitional help sheet); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volitional help sheet | Arm Label: Intervention (volitional help sheet); Type: EXPERIMENTAL; Interventions: Behavioral: Volitional help sheet | Intervention Type: BEHAVIORAL; Name: Volitional help sheet; Assigned to Arm(s): Control (volitional help sheet) | Intervention Type: BEHAVIORAL; Name: Volitional help sheet; Assigned to Arm(s): Intervention (volitional help sheet)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short Message System (SMS) Monitoring Intended for the Suicidal Patients: Study of Efficiency
Brief Summary: The study wants to prove that SMS monitoring reduced the number of suicide attempts in six months according to the beginning of its implementation in the group of the patients benefiting SMS compared with the group of patients benefiting from the usual care.


Options:
A: Arm Label: SMS; Type: EXPERIMENTAL; Interventions: Device: SMS contact with patient after discharge in intervention group | Arm Label: Without SMS; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: SMS contact with patient after discharge in intervention group; Assigned to Arm(s): SMS
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Psychiatric Management | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Intervention Type: BEHAVIORAL; Name: General Psychiatric Management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): 2
C: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
D: Arm Label: Intervention Group ASSIP; Type: EXPERIMENTAL; Interventions: Behavioral: Attempted Suicide Short Intervention Program (ASSIP) | Arm Label: Control Group CG; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Group (CG) | Intervention Type: BEHAVIORAL; Name: Attempted Suicide Short Intervention Program (ASSIP); Assigned to Arm(s): Intervention Group ASSIP | Intervention Type: BEHAVIORAL; Name: Control Group (CG); Assigned to Arm(s): Control Group CG

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Nasal High-flow vs Venturi Mask Oxygen Therapy on Weaning Outcome: a Multicenter, Randomized, Controlled Trial
Brief Summary: The purpose of this study is to determine whether, as compared with the Venturi mask, a nasal, high-flow oxygenation device (Optiflow) may reduce the extubation failure rate in patients needing oxygen therapy after extubation.


Options:
A: Arm Label: HFNC (High Flow Nasal Cannulae); Type: EXPERIMENTAL; Interventions: Device: HFNC | Arm Label: CON (control); Type: ACTIVE_COMPARATOR; Interventions: Device: CON (control) | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC (High Flow Nasal Cannulae) | Intervention Type: DEVICE; Name: CON (control); Assigned to Arm(s): CON (control)
B: Arm Label: THRIVE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: THRIVE with nasopharyngeal airway; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasopharyngeal airway | Intervention Type: DEVICE; Name: Nasopharyngeal airway; Assigned to Arm(s): THRIVE with nasopharyngeal airway
C: Arm Label: Nasal high-flow oxygen therapy; Type: EXPERIMENTAL; Interventions: Device: Optiflow (Fisher & Paykel Healthcare) | Arm Label: Venturi mask oxygen therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask | Intervention Type: DEVICE; Name: Optiflow (Fisher & Paykel Healthcare); Assigned to Arm(s): Nasal high-flow oxygen therapy | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi mask oxygen therapy
D: Arm Label: VL and AO; Type: ACTIVE_COMPARATOR; Interventions: Device: Apneic Oxygenation, Device: No Apneic Oxygenation | Arm Label: DL and AO; Type: ACTIVE_COMPARATOR; Interventions: Device: Apneic Oxygenation, Device: No Apneic Oxygenation | Arm Label: VL and no AO; Type: ACTIVE_COMPARATOR; Interventions: Device: Video Laryngoscopy, Device: Direct Laryngoscopy | Arm Label: DL and no AO; Type: ACTIVE_COMPARATOR; Interventions: Device: Video Laryngoscopy, Device: Direct Laryngoscopy | Intervention Type: DEVICE; Name: Video Laryngoscopy; Assigned to Arm(s): DL and no AO, VL and no AO | Intervention Type: DEVICE; Name: Apneic Oxygenation; Assigned to Arm(s): DL and AO, VL and AO | Intervention Type: DEVICE; Name: Direct Laryngoscopy; Assigned to Arm(s): DL and no AO, VL and no AO | Intervention Type: DEVICE; Name: No Apneic Oxygenation; Assigned to Arm(s): DL and AO, VL and AO

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Azithromycin in Treatment of Bronchiectasis
Brief Summary: Bronchiectasis is a chronic lung condition characterised primarily by dilatation of the airways. Only a small number of clinical studies have been conducted investigating the use of macrolides to treat non-cystic fibrosis bronchiectasis. The purpose of this study is to determine the efficacy of 12 weeks treatment with azithromycin in adult patients with non-cystic fibrosis bronchiectasis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
B: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin
D: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Azithromycin in Treatment of Bronchiectasis
Brief Summary: Bronchiectasis is a chronic lung condition characterised primarily by dilatation of the airways. Only a small number of clinical studies have been conducted investigating the use of macrolides to treat non-cystic fibrosis bronchiectasis. The purpose of this study is to determine the efficacy of 12 weeks treatment with azithromycin in adult patients with non-cystic fibrosis bronchiectasis.


Options:
A: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin
C: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2
D: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Azithromycin in Treatment of Bronchiectasis
Brief Summary: Bronchiectasis is a chronic lung condition characterised primarily by dilatation of the airways. Only a small number of clinical studies have been conducted investigating the use of macrolides to treat non-cystic fibrosis bronchiectasis. The purpose of this study is to determine the efficacy of 12 weeks treatment with azithromycin in adult patients with non-cystic fibrosis bronchiectasis.


Options:
A: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin
B: Arm Label: Mannitol; Type: EXPERIMENTAL; Interventions: Drug: Inhaled mannitol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched control | Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): Mannitol | Intervention Type: DRUG; Name: Matched control; Assigned to Arm(s): Control
C: Arm Label: OM-85; Type: EXPERIMENTAL; Interventions: Drug: OM-85 BV | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: OM-85 BV | Intervention Type: DRUG; Name: OM-85 BV; Assigned to Arm(s): OM-85, Placebo
D: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program

Answer: A